Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...56789101112131415...5960»
  • ||||||||||  lignocaine / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  ultradian: Dynamic Hormone Diagnostics in Endocrine Disease (clinicaltrials.gov) -  Nov 15, 2023   
    P=N/A,  N=528, Completed, 
    Favorable outcomes can be achieved in this subset of PAs with evolving TF classification. Unknown status --> Completed | N=350 --> 528 | Trial completion date: Sep 2020 --> Nov 2023 | Trial primary completion date: Sep 2020 --> Nov 2023
  • ||||||||||  Review, Journal:  Myocardial, Valvular, and Vascular Structural and Functional Properties in Acromegaly. (Pubmed Central) -  Nov 14, 2023   
    Moreover, some valvular and vascular abnormalities are also associated with acromegaly. This present review aims to summarize available information regarding acromegaly-associated abnormalities in myocardial, valvular, and vascular structural and functional properties and their relationship to disease activity and treatment options.
  • ||||||||||  Journal, Surgery:  Endoscopic endonasal transsphenoidal surgery in acromegaly with conchal sphenoid sinus. (Pubmed Central) -  Nov 13, 2023   
    Based on this surgical case, the conchal sphenoid sinus of acromegaly is not always homogeneous solid bone but may contain soft fatty tissue. Therefore, although the sphenoidal characteristics may have an impact on the surgical procedures, precise assessment pre- and intraoperatively can make transsphenoidal surgery with conchal sphenoid sinus feasible.
  • ||||||||||  Review, Journal:  Use of speckle tracking echocardiography in evaluating cardiac dysfunction in patients with acromegaly: an update. (Pubmed Central) -  Nov 10, 2023   
    This information aids in determining the optimal timing for interventional therapy, offering important insights for cardiac risk stratification and prognosis. In the present study, we comprehensively reviewed the research progress of speckle tracking echocardiography in evaluating of cardiac dysfunction in acromegaly patients, to pave the way for early diagnosis of acromegaly cardiomyopathy.
  • ||||||||||  Retrospective data, Journal, Surgery:  Pituitary surgery outcome in patients 75 (Pubmed Central) -  Nov 6, 2023   
    In order to facilitate and standardize the clinical procedures for this type of tumor, this document gathers the positioning of the Neuroendocrinology Knowledge Area of the Spanish Society of Endocrinology and Nutrition (SEEN) and the Spanish Society of Neurosurgery (SENEC) on the management of patients with PTs and their preoperative, surgical and postoperative follow-up. Surgery beyond the age of 75, mainly relying on an endoscopic endonasal transsellar approach, is effective and safe, provided that patients are managed in tertiary centers.
  • ||||||||||  Review, Journal:  Sociodemographic Factors in Pituitary Adenomas. (Pubmed Central) -  Oct 31, 2023   
    The likelihood of surgery at high-volume centers is lower for patients of Black or Hispanic background, uninsured or with lower socioeconomic status. Multicentric studies are necessary to delineate the influence of sociodemographic factors according to the adenoma type and to address the causes of health care disparities.
  • ||||||||||  Journal:  Multiomics Approach to Acromegaly: Unveiling Translational Insights for Precision Medicine. (Pubmed Central) -  Oct 30, 2023   
    We discuss the potential implications of multiomics data integration in the development of novel diagnostic tools, identification of therapeutic targets, and the prospects of precision medicine in acromegaly management. By integrating diverse omics datasets, these approaches can provide valuable insights into disease mechanisms, facilitate the identification of diagnostic biomarkers, and identify potential therapeutic targets for precision medicine in the management of acromegaly.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Journal:  New insights in the pathophysiology, epidemiology and response to treatment of osteoporotic vertebral fractures. (Pubmed Central) -  Oct 22, 2023   
    Endocrinologists should be aware of the high likelihood of osteoporotic VFs in patients with endocrine diseases. Though licensed treatments are able to substantially reduce the occurrence of VFs in patients with osteoporosis, the vast majority of recent or ongoing randomized controlled trials in the VF area focus on advanced invasive therapy of the fracture itself.
  • ||||||||||  Journal:  Do neurosteroids have impact on depression and cognitive functions in cases with acromegaly? (Pubmed Central) -  Oct 22, 2023   
    Though licensed treatments are able to substantially reduce the occurrence of VFs in patients with osteoporosis, the vast majority of recent or ongoing randomized controlled trials in the VF area focus on advanced invasive therapy of the fracture itself. Cognitive changes may be encountered in acromegaly and, neurosteroids may contribute to the changes in certain cognitive functions.
  • ||||||||||  octreotide injection (SYHX2008) / CSPC Pharma
    Trial completion:  A Single-dose Study of Octreotide Injection in Healthy Adult Subjects (clinicaltrials.gov) -  Oct 9, 2023   
    P1,  N=56, Completed, 
    Successfully cured patients have significantly fewer complications than pharmacologically controlled patients and patients with active acromegaly. Recruiting --> Completed
  • ||||||||||  Journal:  Persistent Deficits in Bone Quality in Treated Acromegaly: Evidence From Assessments of Microstructure. (Pubmed Central) -  Oct 9, 2023   
    We show, for the first time, that volumetric bone mineral density and microarchitecture of the peripheral skeleton improve with acromegaly treatment but remain abnormal in patients in remission after surgery compared to controls. These abnormalities, known to be associated with fractures in other populations, may play a role in the pathogenesis of persistent fragility in treated acromegaly.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Journal:  Preference of acromegaly patients for treatment attributes in Spain. (Pubmed Central) -  Oct 2, 2023   
    QoL greatly influences patient treatment preference. Since acromegaly patients are informed and aware of their disease, treatment choices should always be shared with patients.
  • ||||||||||  Trial completion date, Trial primary completion date:  IpoProAcro: Hypoproteic Diet in Acromegaly (clinicaltrials.gov) -  Sep 28, 2023   
    P=N/A,  N=12, Not yet recruiting, 
    In this review, we lay out the complexity of the GHR isoforms and provide an overview of the major pharmacogenetic research conducted on this ongoing and unresolved subject. Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
  • ||||||||||  Mycapssa (octreotide) / Chiesi
    Review, Journal:  Acromegaly: Pathophysiological Considerations and Treatment Options Including the Evolving Role of Oral Somatostatin Analogs. (Pubmed Central) -  Sep 27, 2023   
    While clinical trial data supports the use of octreotide capsules (Mycapssa) in the pharmacological management of GH and IGF-1 levels, very little data exist regarding the drug's efficacy, tolerability, and use in female or pediatric-specific populations. A better understanding of the efficacy, application, and role of oral octreotide capsules in the long-term medical management of acromegaly in a diversity of populations is imperative to best determine the risks/benefits for the clinician.
  • ||||||||||  Review, Journal:  Skeletal complications in acromegaly. (Pubmed Central) -  Sep 25, 2023   
    Moreover, acromegaly leads to cardiovascular, metabolic and respiratory complications, and thus significantly impairs the quality of life. In this review, authors summarize the pathophysiology, diagnosis, and treatment of bone and joint disease in acromegaly.
  • ||||||||||  Journal:  Results of surgical therapy of functioning pituitary adenomas. (Pubmed Central) -  Sep 22, 2023   
    Surgical therapy in the presented cohort led to the normalisation of hormonal excessive production in 58.6% of cases. A combination of drug therapy and radiotherapeutic methods was necessary in the remaining cases to achieve hormonal remission.
  • ||||||||||  Enrollment open, Trial completion date, Trial primary completion date:  Diet in the Management of Acromegaly (clinicaltrials.gov) -  Sep 21, 2023   
    P=N/A,  N=9, Recruiting, 
    A combination of drug therapy and radiotherapeutic methods was necessary in the remaining cases to achieve hormonal remission. Not yet recruiting --> Recruiting | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
  • ||||||||||  Journal:  Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1. (Pubmed Central) -  Sep 21, 2023   
    PitNETs expressing PIT1 and SF1 represent multilineage PitNETs. These rare tumors have variable clinical and morphological features, most often presenting as large tumors with GH excess and occasionally as one of multiple synchronous PitNETs of distinct lineages.
  • ||||||||||  Journal:  Psychopathology in Acromegaly - Real and Perceived. (Pubmed Central) -  Sep 19, 2023   
    The personality disorders also commonly associated with acromegaly, especially due to body image suffering, is linked to sexual dysfunction, which seems to affect women more than men. In summary, psychopathology in acromegaly is a major determinant of the quality of life and a complex array of psychological abnormalities are associated with acromegaly.
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal, HEOR, Real-world evidence, Adherence, Real-world:  Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis. (Pubmed Central) -  Sep 14, 2023   
    Patients with more comorbidities had more health care visits during the first year after diagnosis, suggesting increased disease burden. Real-world evidence on treatment patterns provides insights into recommendations for individualized therapy.